title: Myocardial 11C-diacylglycerol accumulation and left ventricular remodeling in patients after myocardial infarction.
abstract: Left ventricular (LV) remodeling after myocardial infarction (MI) is a maladaptive process that increases the risk of heart failure and death. The myocardial phosphoinositide cycle, which is located downstream from several neurohumoral factors, plays a crucial role in LV remodeling. Our animal studies demonstrated that 1-[1-11C]butyryl-2-palmitoyl-rac-glycerol (11C-DAG) can be used to visualize regions with an activated phosphoinositide cycle. Therefore, we examined whether myocardial 11C-DAG accumulation assessed by PET is relevant to LV enlargement and systolic dysfunction in post-MI patients.
  
  
  METHODS
  We performed PET with 11C-DAG in 13 post-anteroseptal MI patients and 4 healthy volunteers. We placed regions of interest on the noninfarcted myocardium and calculated the myocardium-to-left atrial (LA) chamber ratio of 11C-DAG accumulation.
  
  
  RESULTS
  The myocardium-to-LA chamber ratio of 11C-DAG was significantly higher in the post-MI patients (mean +/- SD, 1.73 +/- 0.35) compared with that of the healthy volunteers (mean +/- SD, 1.25 +/- 0.13; P < 0.05). In the post-MI patients, the myocardium-to-LA chamber ratio of (11)C-DAG was significantly correlated with the LV end-diastolic volume index (r = 0.79, P < 0.01) and the plasma concentration of brain natriuretic peptide (r = 0.85, P < 0.001) and negatively correlated with the LV ejection fraction (r = -0.69, P < 0.01).
  
  
  CONCLUSIONS
  These findings suggest that the myocardial 11C-DAG accumulation assessed by PET is relevant to LV enlargement, LV systolic dysfunction, and humoral activation in post-MI patients. This new imaging strategy based on intracellular signaling may contribute to the assessment and treatment of post-MI patients.
authors.affiliation: Department of Cardiovascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Otani
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Kagaya
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Imahori
authors.forename: Satoshi
authors.initials: S
authors.lastname: Yasuda
authors.forename: Ryo
authors.initials: R
authors.lastname: Fujii
authors.forename: Masanobu
authors.initials: M
authors.lastname: Chida
authors.forename: Shigeto
authors.initials: S
authors.lastname: Namiuchi
authors.forename: Morihiko
authors.initials: M
authors.lastname: Takeda
authors.forename: Masahito
authors.initials: M
authors.lastname: Sakuma
authors.forename: Jun
authors.initials: J
authors.lastname: Watanabe
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Ido
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Nonogi
authors.forename: Kunio
authors.initials: K
authors.lastname: Shirato
mesh_terms: D000328:Adult; D000368:Aged; D005260:Female; D005989:Glycerides / Q000493:pharmacokinetics*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000000981:diagnostic imaging* / Q000378:metabolism*; D011877:Radionuclide Imaging; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic; D018487:Ventricular Dysfunction, Left / Q000000981:diagnostic imaging* / Q000209:etiology / Q000378:metabolism*; D020257:Ventricular Remodeling / Q000502:physiology*
chemical_list: C121883:1-butyryl-2-palmitoyl-rac-glycerol; D005989:Glycerides; D019275:Radiopharmaceuticals